140 related articles for article (PubMed ID: 30417194)
1. Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Liu BY; He XY; Zhuo RX; Cheng SX
Nanoscale; 2018 Dec; 10(45):21209-21218. PubMed ID: 30417194
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Liu BY; He XY; Zhuo RX; Cheng SX
J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905
[TBL] [Abstract][Full Text] [Related]
3. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851
[TBL] [Abstract][Full Text] [Related]
4. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
[TBL] [Abstract][Full Text] [Related]
5. A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
Liu BY; He XY; Xu C; Xu L; Ai SL; Cheng SX; Zhuo RX
Biomacromolecules; 2018 Jul; 19(7):2957-2968. PubMed ID: 29617556
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
8. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-functionalized albumin-based nanoparticles for targeted drug delivery.
Xu L; He XY; Liu BY; Xu C; Ai SL; Zhuo RX; Cheng SX
Colloids Surf B Biointerfaces; 2018 Nov; 171():24-30. PubMed ID: 30005287
[TBL] [Abstract][Full Text] [Related]
11. A novel dual-targeting delivery system for specific delivery of CRISPR/Cas9 using hyaluronic acid, chitosan and AS1411.
Khademi Z; Ramezani M; Alibolandi M; Zirak MR; Salmasi Z; Abnous K; Taghdisi SM
Carbohydr Polym; 2022 Sep; 292():119691. PubMed ID: 35725215
[TBL] [Abstract][Full Text] [Related]
12. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy.
Ren XH; Xu C; Li LL; Zuo Y; Han D; He XY; Cheng SX
J Control Release; 2022 Mar; 343():645-656. PubMed ID: 35157940
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 Assisted Multiplex Genome Editing Technique in Escherichia coli.
Feng X; Zhao D; Zhang X; Ding X; Bi C
Biotechnol J; 2018 Sep; 13(9):e1700604. PubMed ID: 29790644
[TBL] [Abstract][Full Text] [Related]
14. Assembly of CRISPR ribonucleoproteins with biotinylated oligonucleotides via an RNA aptamer for precise gene editing.
Carlson-Stevermer J; Abdeen AA; Kohlenberg L; Goedland M; Molugu K; Lou M; Saha K
Nat Commun; 2017 Nov; 8(1):1711. PubMed ID: 29167458
[TBL] [Abstract][Full Text] [Related]
15. Self-Assembled Plasmid Delivery System for PPM1D Knockout to Reverse Tumor Malignancy.
Ren XH; He XY; Liu BY; Xu C; Cheng SX
ACS Appl Bio Mater; 2020 Nov; 3(11):7831-7839. PubMed ID: 35019523
[TBL] [Abstract][Full Text] [Related]
16. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers.
Schuh RS; de Carvalho TG; Giugliani R; Matte U; Baldo G; Teixeira HF
Eur J Pharm Biopharm; 2018 Jan; 122():158-166. PubMed ID: 29122734
[TBL] [Abstract][Full Text] [Related]
17. Aptamer-Functionalized and Backbone Redox-Responsive Hyperbranched Polymer for Targeted Drug Delivery in Cancer Therapy.
Zhuang Y; Deng H; Su Y; He L; Wang R; Tong G; He D; Zhu X
Biomacromolecules; 2016 Jun; 17(6):2050-62. PubMed ID: 27113017
[TBL] [Abstract][Full Text] [Related]
18. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
[TBL] [Abstract][Full Text] [Related]
19. Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.
Jensen KT; Fløe L; Petersen TS; Huang J; Xu F; Bolund L; Luo Y; Lin L
FEBS Lett; 2017 Jul; 591(13):1892-1901. PubMed ID: 28580607
[TBL] [Abstract][Full Text] [Related]
20. Temperature effect on CRISPR-Cas9 mediated genome editing.
Xiang G; Zhang X; An C; Cheng C; Wang H
J Genet Genomics; 2017 Apr; 44(4):199-205. PubMed ID: 28412228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
